ACR Congratulates Sirtex Medical on FDA Approval of Its SIR-Spheres to Treat Liver Cancer

The ACR® Center for Research and Innovation (CRI®) served as the imaging contract research organization for the DOORwaY⁹⁰ clinical trial that contributed to FDA approval of Sirtex SIR-Spheres technology for liver cancer treatment.

CRI’s management of image and data collection, quality control, and central review of 600 CT/MRI scans from 65 subjects across 12 sites using five expert reviewers was critical to the success of the trial.

Interim analysis of the DOORwaY⁹⁰ trial revealed that 98.5% of patients had the Best Overall Response Rate through nine months and 100% of all evaluable patients were able to demonstrate local tumor control.